CEO
Daejoong Life Science
Seoul, South Korea
I am a CEO of StarryBio which was established strategically to acquire the US phase 3 dosing completed asset for the Greater China right and the US right.
I began my career as a Korean patent attorney after graduating Seoul National University with a major of Chemical & Biological Engineering.
I spent many years in intellectual property practice as a managing partner of IP law firm based in Seoul, Korea, with a strong focus on life sciences and biotechnology.
In 2018, I founded "Daejoong Life Science", expanding my work beyond traditional IP services into strategic advisory and venture creation. Since then, I have been advising biotech and medtech companies and investors on IP strategy, licensing, fundraising, and cross-border transactions.
Currently, we are exploring potential acquisitions of US phase 3 clinical trial dosing completed Knee OA(Knee OsteoArthritis) asset for the Greater China region right and for the US market right both.
We strategically prepared a biotech, StarryBio, a newly formed NewCo, to invite interested investors and after acquisitions, we would like to further develop and commercialize TG-C in the Greater China region and the US market.
We already met diverse investors including global investors and some showed soft interest to be co-leading investors.
Project
Project for Potential Osteoarthritis Global Player
Commercialization after Acquisition of US phase 3 dosing completed asset in the territory of "the Greater China market right" and "US market right" both.